Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6021273 | Neurobiology of Disease | 2016 | 31 Pages |
Abstract
Mutations in phosphatase and tensin homolog (PTEN) have been linked to a subset of individuals with autism and macrocephaly, as well as Cowden Syndrome and focal cortical dysplasia. Pten loss leads to neuronal hypertrophy, but the role of Pten in neuronal migration is unclear. Here we have shown that loss of Pten leads to aberrant migration, which can be prevented but not reversed by treatment with rapamycin, a mTor inhibitor. These results are important to consider as clinical trials are developed to examine rapamycin as a therapeutic for autism with PTEN mutations. Our findings show that some abnormalities cannot be reversed, and suggest the potential need for genetic screening and preventative treatment.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Stephanie A. Getz, Tyrone Jr, Meijie Li, Bryan W. Luikart,